Akebia Ther (AKBA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Akebia Ther stock (AKBA) is currently trading at $1.36. Akebia Ther PS ratio (Price-to-Sales) is 1.61. Analyst consensus price target for AKBA is $4.40. WallStSmart rates AKBA as Sell.
- AKBA PE ratio analysis and historical PE chart
- AKBA PS ratio (Price-to-Sales) history and trend
- AKBA intrinsic value — DCF, Graham Number, EPV models
- AKBA stock price prediction 2025 2026 2027 2028 2029 2030
- AKBA fair value vs current price
- AKBA insider transactions and insider buying
- Is AKBA undervalued or overvalued?
- Akebia Ther financial analysis — revenue, earnings, cash flow
- AKBA Piotroski F-Score and Altman Z-Score
- AKBA analyst price target and Smart Rating
Akebia Ther
📊 No data available
Try selecting a different time range
Smart Analysis
Akebia Ther (AKBA) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, revenue growth. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Akebia Ther (AKBA) Key Strengths (2)
Paying $1.61 for every $1 of annual revenue
Strong revenue growth at 23.90% annually
Supporting Valuation Data
Akebia Ther (AKBA) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 11.7x book value
Small-cap company with higher risk but more growth potential
Moderate institutional interest at 47.59%
Supporting Valuation Data
Akebia Ther (AKBA) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 8.0/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Revenue Growth. Valuation metrics including Price/Sales (1.61) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 23.90%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Book (11.66) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -553.00%, Operating Margin at -10.50%, Profit Margin at -2.26%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -553.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 23.90% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AKBA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AKBA's Price-to-Sales ratio of 1.61x trades at a deep discount to its historical average of 799.74x (19th percentile). The current valuation is 100% below its historical high of 4896.27x set in Dec 2015, and 403% above its historical low of 0.32x in Nov 2022. Over the past 12 months, the PS ratio has compressed from ~3.2x as trailing revenue scaled faster than the stock price.
Compare AKBA with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Akebia Ther (AKBA) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Akebia Ther is a strong growth company balancing expansion with improving profitability. Revenue reached 236M with 24% growth year-over-year. The company is currently unprofitable, posting a -226.0% profit margin.
Key Findings
Generating 31M in free cash flow and 31M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -226.0% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can Akebia Ther maintain 24%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Akebia Ther.
Bottom Line
Akebia Ther offers an attractive blend of growth (24% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Akebia Ther(AKBA)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.